Human ovarian carcinoma-associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Accumulating evidence suggests that mesenchymal stem cells (MSCs) are recruited to the tumor microenvironment; however, controversy exists regarding their role in solid tumors. In this study, we identified and confirmed the presence of carcinoma-associated MSCs (CA-MSCs) in the majority of human ovarian tumor samples that we analyzed. These CA-MSCs had a normal morphologic appearance, a normal karyotype, and were nontumorigenic. CA-MSCs were multipotent with capacity for differentiating into adipose, cartilage, and bone. When combined with tumor cells in vivo, CA-MSCs promoted tumor growth more effectively than did control MSCs. In vitro and in vivo studies suggested that CA-MSCs promoted tumor growth by increasing the number of cancer stem cells. Although CA-MSCs expressed traditional MSCs markers, they had an expression profile distinct from that of MSCs from healthy individuals, including increased expression of BMP2, BMP4, and BMP6. Importantly, BMP2 treatment in vitro mimicked the effects of CA-MSCs on cancer stem cells, while inhibiting BMP signaling in vitro and in vivo partly abrogated MSC-promoted tumor growth. Taken together, our data suggest that MSCs in the ovarian tumor microenvironment have an expression profile that promotes tumorigenesis and that BMP inhibition may be an effective therapeutic approach for ovarian cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The tumor-supporting properties of MSC (immunomodulation, angiogenesis, cell survival or migration) often seem to be enhanced in tumor-derived MSC populations [45, 74, 75].”
From Mesenchymal stem cell secretome and regenerative therapy after cancer (2013) · cites this paper as [45]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multilineage potential of adult human mesenchymal stem cells
Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., Mosca, J. D., Moorman, M. A., Simonetti, D. W., Craig, S., & Marshak, D. R. (1999) · Science · doi:10.1126/science.284.5411.143 · Cited by 21,052
A perivascular origin for mesenchymal stem cells in multiple human organs
Crisan, M., Yap, S., Casteilla, L., Chen, C.-W., Corselli, M., Park, T. S., Andriolo, G., Sun, B., Zheng, B., Zhang, L., et al. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2008.07.003 · Cited by 3,991
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
Karnoub, A. E., Dash, A. B., Vo, A. P., Sullivan, A., Brooks, M. W., Bell, G. W., Richardson, A. L., Polyak, K., Tubo, R., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06188 · Cited by 3,206
Chamberlain, G., Fox, J., Ashton, B., & Middleton, J. (2007) · Stem Cells · doi:10.1634/stemcells.2007-0197 · Cited by 2,381
Genes Expressed in Human Tumor Endothelium
Croix, B. S., Rago, C., Velculescu, V., Traverso, G., Romans, K. E., Montgomery, E., Lal, A., Riggins, G. J., Lengauer, C., Vogelstein, B., et al. (2000) · Science · doi:10.1126/science.289.5482.1197 · Cited by 1,845
Efficient tumour formation by single human melanoma cells
Quintana, E., Shackleton, M., Sabel, M. S., Fullen, D. R., Johnson, T. M., & Morrison, S. J. (2008) · Nature · doi:10.1038/nature07567 · Cited by 1,796
Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals
Djouad, F., Plence, P., Bony, C., Tropel, P., Apparailly, F., Sany, J., Noël, D., & Jorgensen, C. (2003) · Blood · doi:10.1182/blood-2003-04-1193 · Cited by 1,166
Role of tumor-associated macrophages in tumor progression and invasion
Mantovani, A., Schioppa, T., Porta, C., Allavena, P., & Sica, A. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9001-7 · Cited by 888
Spaeth, E. L., Dembinski, J. L., Sasser, A. K., Watson, K., Klopp, A., Hall, B., Andreeff, M., & Marini, F. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004992 · Cited by 807
Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks
Liu, S., Ginestier, C., Ou, S. J., Clouthier, S. G., Patel, S. H., Monville, F., Korkaya, H., Heath, A., Dutcher, J., Kleer, C. G., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-0538 · Cited by 611
Research works printed but not linked: 2
- 10.1634/stemcells.2008-0037 · DOI
- Ye, 2007, Histol Histopathol., 22, 1129
Cited by
Molecular mechanisms of cancer development in obesity
Khandekar, M. J., Cohen, P., & Spiegelman, B. M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3174 · Cited by 907
Challenges and advances in clinical applications of mesenchymal stromal cells
Zhou, T., Yuan, Z., Weng, J., Pei, D., Du, X., He, C., & Lai, P. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01037-x · Cited by 712
“discovered cancerassociated MSCs (CA-MSCs), which are determined by the expression of CD44, CD73, and CD90, exhibited the upregulation of the TGF-β superfamily/bone morphogenetic protein (BMP) family [53], and MSCs harbored the potential to differentiate into cancer-associated fibroblasts (CAFs) at latter passages [54…”
BackgroundEndMT contributes to the onset and progression of cerebral cavernous malformations
Maddaluno, L., Rudini, N., Cuttano, R., Bravi, L., Giampietro, C., Corada, M., Ferrarini, L., Orsenigo, F., Papa, E., Boulday, G., et al. (2013) · Nature · doi:10.1038/nature12207 · Cited by 486
Ahmed, N., & Stenvers, K. L. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00256 · Cited by 482
“On the other hand, non-resident cells within the ascites include non-cancer cells such as inflammatory cells, immature myeloid cells and activated mesothelial cells, and MSCs (which can be resident or non-resident) (68), all of which influence tumor cell behavior and response to chemotherapy (69).”
BackgroundTumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets
Shi, Y., Du, L., Lin, L., & Wang, Y. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.193 · Cited by 460
The LIN28/let-7 Pathway in Cancer
Balzeau, J., Menezes, M. R., Cao, S., & Hagan, J. P. (2017) · Frontiers in Genetics · doi:10.3389/fgene.2017.00031 · Cited by 447
“Furthermore, in vitro treatment with exogeneous BMP2 increased growth of ovarian CSCs, whereas in vitro and in vivo inhibition of BMP signaling partly abrogated mesenchymal stem cell-induced tumor growth (McLean et al., 2011).”
BackgroundThe role of stromal cancer-associated fibroblasts in pancreatic cancer
von Ahrens, D., Bhagat, T. D., Nagrath, D., Maitra, A., & Verma, A. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0448-5 · Cited by 389
Beyond TGFβ: roles of other TGFβ superfamily members in cancer
Wakefield, L. M., & Hill, C. S. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3500 · Cited by 374
Targeting the tumor stroma for cancer therapy
Xu, M., Zhang, T., Xia, R., Wei, Y., & Wei, X. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01670-1 · Cited by 319
“Moreover, TA-MSCs were determined to facilitate tumor cell proliferation by increasing cancer stem cell numbers and augmenting BMP production [197].”
BackgroundPapaccio, F., Paino, F., Regad, T., Papaccio, G., Desiderio, V., & Tirino, V. (2017) · Stem Cells Translational Medicine · doi:10.1002/sctm.17-0138 · Cited by 292
Stable expansion of high‐grade serous ovarian cancer organoids requires a low‐Wnt environment
Hoffmann, K., Berger, H., Kulbe, H., Thillainadarasan, S., Mollenkopf, H., Zemojtel, T., Taube, E., Darb‐Esfahani, S., Mangler, M., Sehouli, J., et al. (2020) · The EMBO Journal · doi:10.15252/embj.2019104013 · Cited by 252
“Although some properties of cancer stem cells in HGSOC have been described (McLean et al , 2011; Choi et al , 2015; Lupia & Cavallaro, 2017), there is no knowledge about the intrinsic mechanisms that drive tumor growth and mediate recurrent disease.”
The roles of mesenchymal stem cells in tumor inflammatory microenvironment
Sun, Z., Wang, S., & Zhao, R. C. (2014) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-7-14 · Cited by 249
“T-MSCs and N-MSCs have similar phenotypes [48-52]; in particular, both types of MSCs express high levels of CD29, CD44, CD90, and CD105, but low levels of hematopoietic cell markers.”
BackgroundResultInfluentialMelzer, C., Rehn, V., Yang, Y., Bähre, H., von der Ohe, J., & Hass, R. (2019) · Cancers · doi:10.3390/cancers11060798 · Cited by 245
The double edge sword of fibrosis in cancer
Chandler, C., Liu, T., Buckanovich, R., & Coffman, L. G. (2019) · Translational Research · doi:10.1016/j.trsl.2019.02.006 · Cited by 242
Self-citationLatifi, A., Luwor, R. B., Bilandzic, M., Nazaretian, S., Stenvers, K., Pyman, J., Zhu, H., Thompson, E. W., Quinn, M. A., Findlay, J. K., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046858 · Cited by 240
Zhang, T., Lee, Y. W., Rui, Y. F., Cheng, T. Y., Jiang, X. H., & Li, G. (2013) · Stem Cell Research & Therapy · doi:10.1186/scrt221 · Cited by 234
“Moreover, the interaction of MSCs with tumor cells to promote angiogenesis could also be found in human ovarian carcinoma cells and melanoma cancer cells [44,45].”
BackgroundYan, X., Zhang, D., Wu, W., Wu, S., Qian, J., Hao, Y., Yan, F., Zhu, P., Wu, J., Huang, G., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1915 · Cited by 233
“It has been increasingly recognized that cancer-associated MSCs act as important contributors to tumor progression (20) (36).”
BackgroundWang, M., Zhao, C., Shi, H., Zhang, B., Zhang, L., Zhang, X., Wang, S., Wu, X., Yang, T., Huang, F., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.14 · Cited by 230
Current and future immunotherapeutic approaches in pancreatic cancer treatment
Farhangnia, P., Khorramdelazad, H., Nickho, H., & Delbandi, A.-A. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01561-6 · Cited by 229
Isolation, identification, and characterization of cancer stem cells: A review
Abbaszadegan, M. R., Bagheri, V., Razavi, M. S., Momtazi, A. A., Sahebkar, A., & Gholamin, M. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25759 · Cited by 225
“Moreover, links between BMP signaling and CSC functions were well-established in ovarian cancer (McLean et al., 2011), CML (Laperrousaz et al.”
BackgroundHossain, A., Gumin, J., Gao, F., Figueroa, J., Shinojima, N., Takezaki, T., Priebe, W., Villarreal, D., Kang, S.-G., Joyce, C., et al. (2015) · Stem Cells · doi:10.1002/stem.2053 · Cited by 224
Motohara, T., Masuda, K., Morotti, M., Zheng, Y., El-Sahhar, S., Chong, K. Y., Wietek, N., Alsaadi, A., Carrami, E. M., Hu, Z., et al. (2019) · Oncogene · doi:10.1038/s41388-018-0637-x · Cited by 218
Critical role for lysyl oxidase in mesenchymal stem cell-driven breast cancer malignancy
El-Haibi, C. P., Bell, G. W., Zhang, J., Collmann, A. Y., Wood, D., Scherber, C. M., Csizmadia, E., Mariani, O., Zhu, C., Campagne, A., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206653109 · Cited by 218
“Because the protumorigenic and prometastatic functions of stromal MSCs have now been recognized in multiple tumor settings (7, 38), it would be important to exploit such a platform to further characterize the molecular nature of the heterotypic crosstalk that takes place at the tumor to stroma interface.”
BackgroundMesenchymal Stem Cell-Mediated Effects of Tumor Support or Suppression
Rhee, K.-J., Lee, J., & Eom, Y. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161226215 · Cited by 214
“These results imply that MSCs can promote tumor growth by increasing the CSC number through BMP expression [128].”
BackgroundEpithelial ovarian cancer experimental models
Lengyel, E., Burdette, J. E., Kenny, H. A., Matei, D., Pilrose, J., Haluska, P., Nephew, K. P., Hales, D. B., & Stack, M. S. (2014) · Oncogene · doi:10.1038/onc.2013.321 · Cited by 208
Mesenchymal stem cells in tumor development: Emerging roles and concepts
Cuiffo, B. G., & Karnoub, A. E. (2012) · Cell Adhesion & Migration · doi:10.4161/cam.20875 · Cited by 201
“Similarly, tumorassociated MSCs were found to enhance the generation of cancer stem cells in ovarian carcinoma, in this case, via BMP2 signaling.(7) Along similar lines, MSCs have been described to play a role in cancer-cell-resistance to classical chemotherapy.”
BackgroundPhase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer
Brown, J. R., Chan, D. K., Shank, J. J., Griffith, K. A., Fan, H., Szulawski, R., Yang, K., Reynolds, R. K., Johnston, C., McLean, K., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133247 · Cited by 198
“Patient-derived CA-MSCs and normal omental MSCs were cultured as described (37-39), then FACS-sorted for the cell-surface markers CD105, CD90, and CD73 and genomic DNA isolated as above.”
BackgroundMethodInfluentialSelf-citationGM-CSF Mediates Mesenchymal–Epithelial Cross-talk in Pancreatic Cancer
Waghray, M., Yalamanchili, M., Dziubinski, M., Zeinali, M., Erkkinen, M., Yang, H., Schradle, K. A., Urs, S., Pasca Di Magliano, M., Welling, T. H., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0947 · Cited by 197
“It has previously been reported that CA-MSCs (12, 13) and bone marrow MSCs (30) endow tumor cells with invasive and metastatic properties and thereby expedite tumor metastasis.”
BackgroundMethodInfluentialMetformin targets ovarian cancer stem cells in vitro and in vivo
Shank, J. J., Yang, K., Ghannam, J., Cabrera, L., Johnston, C. J., Reynolds, R. K., & Buckanovich, R. J. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.07.115 · Cited by 189
“We also evaluated tumor cellular proliferation rates as detected by Ki67 stain [16].”
Self-citationTesta, U., Petrucci, E., Pasquini, L., Castelli, G., & Pelosi, E. (2018) · Medicines · doi:10.3390/medicines5010016 · Cited by 188
“In this context, a recent study showed that human ovarian carcinoma-associated mesenchymal stem cells are non-tumorigenic, but clearly promoted tumor sphere growth in vitro, associated with an increase in tumor “stemness” [206].”
BackgroundTGF-β family signaling in stem cells
Sakaki-Yumoto, M., Katsuno, Y., & Derynck, R. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2012.08.008 · Cited by 156
Yan, X.-L., Jia, Y.-L., Chen, L., Zeng, Q., Zhou, J.-N., Fu, C.-J., Chen, H.-X., Yuan, H.-F., Li, Z.-W., Shi, L., et al. (2013) · Hepatology · doi:10.1002/hep.26257 · Cited by 185
“Consistent with previous studies, we found LCMSCs significantly promoted tumor formation and enhanced tumor sphere formation.(6) Our study provides the first evidence that solid tumor-associated MSCs can promote cancer metastasis in vivo.”
InfluentialThibault, B., Castells, M., Delord, J.-P., & Couderc, B. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9456-2 · Cited by 184
“However, they exhibit molecular differences such as an increased expression of bone morphogenetic protein (BMP) 2, BMP4, and BMP6 which is responsible for increased tumor growth compared to “normal” MSCs [169].”
BackgroundMesenchymal stem cells as a double-edged sword in tumor growth: focusing on MSC-derived cytokines
Liang, W., Chen, X., Zhang, S., Fang, J., Chen, M., Xu, Y., & Chen, X. (2021) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-020-00246-5 · Cited by 180
“These findings reveal that MSCs can stimulate tumor progression by incrementing the cancer stem cell number via BMP expression [165].”
BackgroundBorriello, L., Nakata, R., Sheard, M. A., Fernandez, G. E., Sposto, R., Malvar, J., Blavier, L., Shimada, H., Asgharzadeh, S., Seeger, R. C., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2586 · Cited by 180
“Since CAF contribute to the progression of many other cancer types like colon (43), endometrial (44), ovarian (10,45), breast (46), and pancreatic (37) cancers, our observations are relevant to cancers other than NB.”
Li, Y.-R., Fang, Y., Lyu, Z., Zhu, Y., & Yang, L. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04575-9 · Cited by 180
“For instance, in ovarian cancer, MSCs have been documented to produce BMP4 and BMP2, thereby amplifying the population of CSCs [67].”
BackgroundCuiffo, B. G., Campagne, A., Bell, G. W., Lembo, A., Orso, F., Lien, E. C., Bhasin, M. K., Raimo, M., Hanson, S. E., Marusyk, A., et al. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.10.001 · Cited by 173
“prostate, or ovarian tumors display promalignant phenotypes indicative of their crucial supportive functions in the progression of these tumors (McLean et al., 2011; Yan et al., 2012; Jung et al., 2013).”
BackgroundMesenchymal stem cell secretome and regenerative therapy after cancer
Zimmerlin, L., Park, T. S., Zambidis, E. T., Donnenberg, V. S., & Donnenberg, A. D. (2013) · Biochimie · doi:10.1016/j.biochi.2013.05.010 · Cited by 168
“TAF, myofibroblasts) often possess augmented ability to promote tumor growth [45, 75, 77, 82] and invasion [74, 75] compared with healthy donor MSC via superior angiogenesis [75, 77, 80, 82, 89], or abnormal immunomodulation [76, 79, 81], resulting in increased release of cytokines/growth factors including hepatocyte…”
BackgroundInfluentialGalland, S., & Stamenkovic, I. (2020) · The Journal of Pathology · doi:10.1002/path.5357 · Cited by 165
“Tumor-associated MSCs do not undergo transformation and are euploid [98,99].”
BackgroundOvarian cancer stem cell markers: Prognostic and therapeutic implications
Burgos-Ojeda, D., Rueda, B. R., & Buckanovich, R. J. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.02.002 · Cited by 163
“We recently demonstrated that bone morphogenetic protein (BMP) inhibitor Noggin, can prevent CSC self-renewal and reduce tumor growth in vivo [86].”
BackgroundSelf-citationA Pan-ALDH1A Inhibitor Induces Necroptosis in Ovarian Cancer Stem-like Cells
Chefetz, I., Grimley, E. C., Yang, K. Y., Hong, L., Vinogradova, E. V., Suciu, R. M., Kovalenko, I., Karnak, D. M., Morgan, C. A., Chtcherbinine, M., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.02.032 · Cited by 161
Self-citationHOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer
Teschendorff, A. E., Lee, S.-H., Jones, A., Fiegl, H., Kalwa, M., Wagner, W., Chindera, K., Evans, I., Dubeau, L., Orjalo, A., et al. (2015) · Genome Medicine · doi:10.1186/s13073-015-0233-4 · Cited by 152
“On the other hand the cancer cell-autonomous tumour stroma and mesenchymal stem cells (MSCs) — mainly recruited from the bone marrow [6] — might play an important role in ovarian cancer biology [7, 8].”
Líbalová, H., Uhlířová, K., Kléma, J., Machala, M., Šrám, R. J., Cigánek, M., & Topinka, J. (2012) · Particle and Fibre Toxicology · doi:10.1186/1743-8977-9-1 · Cited by 153
“In our study, the upregulation of bone morphogenic protein type-2 (BMP2), antagonist of TGF-b involved in osteogenesis, cell differentiation, growth and invasivity, is primarily responsible for TGF-b signaling deregulation [49].”
BackgroundMultiple Myeloma Mesenchymal Stem Cells: Characterization, Origin, and Tumor-Promoting Effects
Reagan, M. R., & Ghobrial, I. M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2212 · Cited by 132
“Overexpression of BMP-2, -4 and -6 in CA-MSCs compared to ND-MSCs and subsequent promotion of the cancer stem cell population was deemed the underlying mechanism of increased tumor growth.(55) Of course, in MM other factors are likely involved since BMP signaling would likely promote osteogenesis, not tumor growth.”
Slow-cycling (dormant) cancer cells in therapy resistance, cancer relapse and metastasis
Basu, S., Yang, D. Y., Kumar, R., Jeter, C. R., & Tang, D. G. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.04.021 · Cited by 150
“CSCs in many tumors are also intrinsically immunodeficient [55,94] and CSCs in some other tumors are protected from immune surveillance by the TME factors such as tenascin-C [87] and TME cells such as mesenchymal stem cells [88,89] and cancer-associated fibroblasts or CAFs [98–100,136].”
BackgroundAvnet, S., Di Pompo, G., Chano, T., Errani, C., Ibrahim-Hashim, A., Gillies, R. J., Donati, D. M., & Baldini, N. (2017) · International Journal of Cancer · doi:10.1002/ijc.30540 · Cited by 132
“The expansion of the CSC fraction in tumor-associated stroma has also been shown in gastric and pancreatic carcinomas.52,53 In ovarian cancer, it was mediated by the expression of BMP2, BMP4 and BMP6.”
BackgroundInfluentialBilyk, O., Coatham, M. L., Jewer, M., & Postovit, L.-M. M. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00145 · Cited by 145
“For example, increased production of BMPs by OC cells and surrounding stroma has been shown to promote tumor growth (207).”
BackgroundCoffman, L. G., Choi, Y.-J., McLean, K., Allen, B. L., di Magliano, M. P., & Buckanovich, R. J. (2016) · Oncotarget · doi:10.18632/oncotarget.6870 · Cited by 127
“CA-MSCs have a unique expression profile compared to normal adipose, bone marrow or ovary derived MSCs characterized by increased BMP expression (particularly BMP2 and BMP4) [14, 16].”
BackgroundResultInfluentialSelf-citationMesenchymal Stem Cell-Induced DDR2 Mediates Stromal-Breast Cancer Interactions and Metastasis Growth
Gonzalez, M. E., Martin, E. E., Anwar, T., Arellano-Garcia, C., Medhora, N., Lama, A., Chen, Y.-C., Tanager, K. S., Yoon, E., Kidwell, K. M., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.079 · Cited by 133
“Similar protocols were described to isolate MSCs from human primary ovarian tumors (McLean et al., 2011).”
MethodInfluentialQian, J., LeSavage, B. L., Hubka, K. M., Ma, C., Natarajan, S., Eggold, J. T., Xiao, Y., Fuh, K. C., Krishnan, V., Enejder, A. M. K., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci146186 · Cited by 138
“In HGSOCs, recent studies have highlighted a role for stromal cells within the peritoneal cavity, including fibroblasts (36, 81), mesenchymal stem cells (82), adipocytes (83), macrophages (81, 84), and myeloid-derived suppressor cells (35), in CSC expansion and maintenance.”
BackgroundMesenchymal stem cells: From regeneration to cancer
Li, P., Gong, Z., Shultz, L. D., & Ren, G. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.04.005 · Cited by 134
Mesenchymal Stem Cells in the Tumor Microenvironment
Atiya, H. I., Frisbie, L. G., Pressimone, C. A., & Coffman, L. G. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-37184-5_3 · Cited by 137
HOXA9 promotes ovarian cancer growth by stimulating cancer-associated fibroblasts
Ko, S. Y., Barengo, N., Ladanyi, A., Lee, J.-S., Marini, F., Lengyel, E., & Naora, H. (2012) · Journal of Clinical Investigation · doi:10.1172/jci62229 · Cited by 132
Organoids with cancer stem cell-like properties secrete exosomes and HSP90 in a 3D nanoenvironment
Eguchi, T., Sogawa, C., Okusha, Y., Uchibe, K., Iinuma, R., Ono, K., Nakano, K., Murakami, J., Itoh, M., Arai, K., et al. (2018) · PLOS ONE · doi:10.1371/journal.pone.0191109 · Cited by 117
MicroRNA MiR-214 Regulates Ovarian Cancer Cell Stemness by Targeting p53/Nanog
Xu, C., Xu, M., Tan, L., Yang, H., Permuth‐Wey, J., Kruk, P. A., Wenham, R. M., Nicosia, S. V., Lancaster, J. M., Sellers, T. A., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.374611 · Cited by 128
RetractedMathew, E., Brannon, A. L., Del Vecchio, A., Garcia, P. E., Penny, M. K., Kane, K. T., Vinta, A., Buckanovich, R. J., & di Magliano, M. P. (2016) · Neoplasia · doi:10.1016/j.neo.2016.01.005 · Cited by 121
“Thus, we measured the relative expression of BMP2 and BMP4 by qRT-PCR in isolated P-MSCs and CA-MSCs.”
BackgroundInfluentialSelf-citationNowicka, A., Marini, F. C., Solley, T. N., Elizondo, P. B., Zhang, Y., Sharp, H. J., Broaddus, R., Kolonin, M., Mok, S. C., Thompson, M. S., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081859 · Cited by 119
“BM-MSCs have been shown to promote cancer cells ability to grow, survive, and migrate by secreting a broad variety of cytokines, chemokines, and growth factors [3-6].”
BackgroundKawase, T., Yasui, Y., Nishina, S., Hara, Y., Yanatori, I., Tomiyama, Y., Nakashima, Y., Yoshida, K., Kishi, F., Nakamura, M., et al. (2015) · BMC Gastroenterology · doi:10.1186/s12876-015-0340-0 · Cited by 111
“Mesenchymal stem cells within tumor stroma have been shown to promote tumor growth and metastatic capacity of cancer cells [36, 37].”
BackgroundLee, M. W., Ryu, S., Kim, D. S., Lee, J. W., Sung, K. W., Koo, H. H., & Yoo, K. H. (2019) · Leukemia · doi:10.1038/s41375-018-0373-9 · Cited by 121
Frisbie, L., Buckanovich, R. J., & Coffman, L. (2022) · Stem Cells · doi:10.1093/stmcls/sxac036 · Cited by 101
Self-citationRecent discoveries concerning the tumor - mesenchymal stem cell interactions
Lazennec, G., & Lam, P. Y. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.10.004 · Cited by 117
“MSCs isolated from ovarian tumors increase the number of cancer stem cells (CSCs) through the Bone morphogenetic protein BMP2 and BMP4 production [49].”
BackgroundRole of MSC in the Tumor Microenvironment
Hass, R. (2020) · Cancers · doi:10.3390/cancers12082107 · Cited by 116
“Moreover, the adaptation of MSC to the ovarian TME was associated with functional changes including the enhanced expression of the bone morphogenic proteins BMP2, BMP4 and BMP6 [46] (Table 1).”
BackgroundNovel strategies for cancer immunotherapy: counter-immunoediting therapy
Liu, S., Sun, Q., & Ren, X. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01430-8 · Cited by 114
“MSCs can enable tumor cells to acquire proliferative and anti-aging features by increasing the number of tumor stem cells, increasing bone morphogenetic protein (BMP) production, and activating the P53/P21 pathway [77, 78].”
BackgroundReinartz, S., Finkernagel, F., Adhikary, T., Rohnalter, V., Schumann, T., Schober, Y., Nockher, W. A., Nist, A., Stiewe, T., Jansen, J. M., et al. (2016) · Genome biology · doi:10.1186/s13059-016-0956-6 · Cited by 113
“Previous studies have also associated BMP2 and BMP4 with ovarian cancer, both of which are expressed at extremely low levels in tumor cells and TAMs (Additional file 3: Dataset S2), which may be explained by the previous identification of ovarian cancer-associated mesenchymal stem cells as a major source of these cyto…”
An integrated analysis identifies STAT4 as a key regulator of ovarian cancer metastasis
Zhao, L., Ji, G., Le, X., Luo, Z., Wang, C., Feng, M., Xu, L., Zhang, Y., Lau, W. B., Lau, B., et al. (2017) · Oncogene · doi:10.1038/onc.2016.487 · Cited by 110
Adipose tissue stem cells: the great WAT hope
Cawthorn, W. P., Scheller, E. L., & MacDougald, O. A. (2012) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.01.003 · Cited by 98
Epithelial and stromal co-evolution and complicity in pancreatic cancer
Hingorani, S. R. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00530-w · Cited by 108
Evidences of Early Senescence in Multiple Myeloma Bone Marrow Mesenchymal Stromal Cells
André, T., Meuleman, N., Stamatopoulos, B., De Bruyn, C., Pieters, K., Bron, D., & Lagneaux, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059756 · Cited by 107
Cascio, S., Chandler, C., Zhang, L., Sinno, S., Gao, B., Onkar, S., Bruno, T. C., Vignali, D. A. A., Mahdi, H., Osmanbeyoglu, H. U., et al. (2021) · Science Advances · doi:10.1126/sciadv.abi5790 · Cited by 107
Self-citationCancer Associated Fibroblasts: Naughty Neighbors That Drive Ovarian Cancer Progression
Dasari, S., Fang, Y., & Mitra, A. K. (2018) · Cancers · doi:10.3390/cancers10110406 · Cited by 103
“Mesenchymal stem cell derived CAFs were also shown to regulate ovarian cancer stem cells through bone morphogenetic protein secretion, which resulted in resistance to chemotherapy [24,25].”
BackgroundRaghavan, S. A., Snyder, C. S., Wang, A., McLean, K., Zamarin, D., Buckanovich, R. J., & Mehta, G. (2020) · Cancers · doi:10.3390/cancers12082063 · Cited by 105
“For CA-MSC from single cell tumor suspensions, cells were plated onto two-dimensional (2D) tissue culture treated plates in an MSC selection medium following protocols outlined previously [28].”
MethodResultSelf-citationCCL2/CCL5 secreted by the stroma induce IL-6/PYK2 dependent chemoresistance in ovarian cancer
Pasquier, J., Gosset, M., Geyl, C., Hoarau-Véchot, J., Chevrot, A., Pocard, M. D., Mirshahi, M., Lis, R., Rafii, A., & Touboul, C. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0787-z · Cited by 103
“Previous report showed that MSCs (CD44+, CD73+, CD90+) represent around 6% of the full cell population in human ovarian tumor ascites [21].”
BackgroundMesenchymal stem cells in the tumor microenvironment
GUAN, J., & Chen, J. (2013) · Biomedical Reports · doi:10.3892/br.2013.103 · Cited by 102
Long, H., Xiang, T., Qi, W., Huang, J., Chen, J., He, L., Liang, Z., Guo, B., Li, Y., Xie, R., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3462 · Cited by 98
BMP-2 induces EMT and breast cancer stemness through Rb and CD44
Huang, P., Chen, A., He, W., Li, Z., Zhang, G., Liu, Z., Liu, G., Liu, X., He, S.-L., Xiao, G., et al. (2017) · Cell Death Discovery · doi:10.1038/cddiscovery.2017.39 · Cited by 97
Burgos-Ojeda, D., WU, R. T., McLean, K., Chen, Y., Talpaz, M., Yoon, E., Cho, K. R., & Buckanovich, R. J. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0607 · Cited by 98
“Sphere assays Sphere culture was performed as previously described (5, 19, 20) with FACS-isolated CD24þ/ , CD44þ/ , CD90þ/ , CD117þ/ , CD133þ/ , and ALDHþ/ cell populations plated in triplicate in either 6-well or 24-well ultralow attachment plates in serum-freeDMEM/F12, epidermal growth factor (EGF) 20ng/mL, gentamyc…”
MethodSelf-citationMesenchymal Stem/Stromal Cells in Stromal Evolution and Cancer Progression
Cammarota, F., & Laukkanen, M. O. (2015) · Stem Cells International · doi:10.1155/2016/4824573 · Cited by 95
“In tumors, the MSCs either differentiate or maintain their primitive phenotype, thus participating in the construction of the stroma and supporting cancer cell growth through their secretion of cytokines and growth factors [55–58].”
Ning, J., Zhao, Y. C., Ye, Y., & Yu, J. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.02.033 · Cited by 95
“and inhibition of the 2 pathways showed an effective therapeutic effect on ovarian cancer [140,141].”
BackgroundCoffman, L. G., Burgos-Ojeda, D., WU, R. T., Cho, K. R., Bai, S., & Buckanovich, R. J. (2016) · Translational research · doi:10.1016/j.trsl.2016.03.016 · Cited by 95
“Our previous work demonstrates that axillary xenografts with ovarian cancer cell lines SKOV3 and CAOV3 do not form metastatic disease.(13,28) We next used primary patient-derived ovarian tumor cells in an axillary xenograft model.”
Self-citationVoorneveld, P. W., Kodach, L. L., Jacobs, R. J., van Noesel, C. J. M., Peppelenbosch, M. P., Korkmaz, K., Molendijk, I., Dekker, E., Morreau, H., van Pelt, G. W., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.560 · Cited by 94
“However, recent research in several tumour types has identified BMP pathway components as stromally produced factors influencing tumour progression (Sneddon et al, 2006; McLean et al, 2011; Karagiannis et al, 2013).”
BackgroundKeita, M., Bachvarova, M., Morin, C., Plante, M., Gregoire, J., Renaud, M., Sebastianelli, A., Trinh, X. B., & Bachvarov, D. R. (2013) · Cell Cycle · doi:10.4161/cc.23963 · Cited by 94
Ovarian cancer stem cells: Molecular concepts and relevance as therapeutic targets
Ahmed, N., Abubaker, K., & Findlay, J. K. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2013.06.002 · Cited by 94
Gedye, C. A., Hussain, A., Paterson, J., Smrke, A., Saini, H., Sirskyj, D., Pereira, K., Lobo, N. C., Stewart, J. M., Go, C. D., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105602 · Cited by 94
“We chose to follow up on CD90, as it has been reported by others to be expressed on mesenchymal stem cells [18], on cells resembling mesenchymal stem cells that were cultured from SOC samples [19], and also to be a CAF marker in prostate cancer [20,21].”
Ovarian Carcinoma-Associated Mesenchymal Stem Cells Arise from Tissue-Specific Normal Stroma
Coffman, L. G., Pearson, A. T., Frisbie, L. G., Freeman, Z., Christie, E., Bowtell, D. D., & Buckanovich, R. J. (2019) · Stem Cells · doi:10.1002/stem.2932 · Cited by 86
Self-citationTumour cell-derived exosomes endow mesenchymal stromal cells with tumour-promotion capabilities
Lin, L. Y., Du, L. M., Cao, K., Huang, Y., Yu, P. F., Zhang, L. Y., Li, F. Y., Wang, Y., & Shi, Y. F. (2016) · Oncogene · doi:10.1038/onc.2016.131 · Cited by 85
Wang, Z.-Q., Bachvarova, M., Morin, C., Plante, M., Gregoire, J., Renaud, M., Sebastianelli, A., & Bachvarov, D. R. (2014) · Oncotarget · doi:10.18632/oncotarget.1652 · Cited by 91
Stem cell-based therapy for malignant glioma
Bexell, D., Svensson, A., & Bengzon, J. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.06.006 · Cited by 85
Leukemia inhibitory factor functions in parallel with interleukin-6 to promote ovarian cancer growth
McLean, K., Tan, L., Bolland, D. E., Coffman, L. G., Peterson, L. F., Talpaz, M., Neamati, N., & Buckanovich, R. J. (2018) · Oncogene · doi:10.1038/s41388-018-0523-6 · Cited by 89
Self-citationMesenchymal stromal cells’ role in tumor microenvironment: involvement of signaling pathways
Kamdje, A. H. N., Kamga, P. T., Simo, R. T., Vecchio, L., Etet, P. F. S., Jm, M., Bassi, G., Lukong, K. E., Goel, R. K., Amvene, J. M., et al. (2017) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2016.0033 · Cited by 88
Identifying an ovarian cancer cell hierarchy regulated by bone morphogenetic protein 2
Choi, Y.-J., Ingram, P. N., Yang, K., Coffman, L., Iyengar, M., Bai, S., Thomas, D. G., Yoon, E., & Buckanovich, R. J. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1507899112 · Cited by 78
“Tumor sphere cultures were performed as previously described (17, 23) using 10,000 primary cells were cultured in mammary epithelial basal medium (MEBM) ± 200 ng/mL BMP2.”
BackgroundMethodSelf-citationOvarian cancer stem cells and their role in drug resistance
Pieterse, Z., Amaya-Padilla, M. A., Singomat, T., Binju, M., Ardyansyah, B. D., Yu, Y., & Kaur, P. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2018.11.012 · Cited by 85
Targeting Cancer Stem Cells to Overcome Therapy Resistance in Ovarian Cancer
Muñoz-Galván, S., & Carnero, A. (2020) · Cells · doi:10.3390/cells9061402 · Cited by 86
“Moreover, tumor-associated MSCs show a distinct expression pattern compared with control MSCs, and they promote higher tumor growth of OC cells, possibly leading to more CSCs in a process that is dependent on bone morphogenetic protein (BMP) signaling [102].”
BackgroundTsai, C.-L., Tsai, C., Lin, C., Chen, H.-W., Lee, Y., Chao, A., Wang, T., Wang, H., & Lai, C. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.07.002 · Cited by 85
de Lourdes Mora-García, M., García-Rocha, R., Morales-Ramírez, O., Montesinos, J. J., Weiss-Steider, B., Hernández-Montes, J., Ávila-Ibarra, L. R., Don-López, C. A., Velasco-Velázquez, M. A., Gutiérrez-Serrano, V., et al. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-1057-8 · Cited by 77
“T-MSCs have been isolated and characterized from ovarian cancer [14], giant cell tumors of bone [15], neuroblastoma [16], osteosarcoma, lipoma [17], gastric cancer [18] and cervical cancer (CeCa) [19].”
BackgroundShahar, T., Rozovski, U., Hess, K. R., Hossain, A., Gumin, J., Gao, F., Fuller, G. N., Goodman, L. D., Sulman, E. P., & Lang, F. F. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now239 · Cited by 85
Li, C., Zhao, H., & Wang, B. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100948 · Cited by 84
Escobar, P., Bouclier, C., Serret, J., Bièche, I., Brigitte, M., Caicedo, A., Sanchez, E., Vacher, S., Vignais, M., Bourin, P., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4732 · Cited by 82
“showed that MSCs could enhance tumor growth by increasing the number of cancer stem cells [15].”
BackgroundFan, H., Atiya, H. I., Wang, Y., Pisanic, T. R., Wang, T., Shih, I., Foy, K. K., Frisbie, L. G., Buckanovich, R. J., Chomiak, A. A., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108473 · Cited by 81
“Efforts to determine what drives the formation and function of the ovarian TME led to the identification of a critical stromal stem cell, the carcinoma-associated mesenchymal stem/ stromal cell (CA-MSC) (McLean et al., 2011).”
InfluentialSelf-citationChapellier, M., Bachelard-Cascales, É., Schmidt, X., Clément, F., Treilleux, I., Delay, E., Jammot, A., Ménétrier‐Caux, C., Pochon, G., Besançon, R., et al. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2014.12.007 · Cited by 81
“Increasing evidence indicates that the microenvironment plays an active role in cancer, such as alterations of mesenchymal stem cells that promote the proliferation and dissemination of cancer cells (McLean et al., 2011).”
BackgroundMesenchymal stem cells and cancer therapy: insights into targeting the tumour vasculature
Aravindhan, S., Ejam, S. S., Lafta, M. H., Markov, A., Yumashev, A. V., & Ahmadi, M. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01836-9 · Cited by 70
Metadata
- Authors
- McLean, K., Gong, Y., Choi, Y., Deng, N., Yang, K., Bai, S., Cabrera, L., Keller, E., McCauley, L., Cho, K. R., & Buckanovich, R. J.
- Affiliations
- University of Michigan (US)
- Corresponding author
- Buckanovich, Ronald J.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2011-08-01
- Volume
- 121
- Issue
- 8
- Pages
- 3206-3219
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3148732
- OpenAlex
- W1970698543
- Cited by
- 380
- References
- 57
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 20 · 2023: 44 · 2022: 29 · 2021: 34 · 2020: 19 · 2019: 25 · 2018: 28 · 2017: 23 · 2016: 30 · 2015: 22 · 2014: 28 · 2013: 28 · 2012: 26
- FWCI
- 13.91
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Damon Runyon Cancer Research Foundation
- University of Michigan (48109)
- College of Pharmacy, University of Michigan
- U.S. Public Health Service (P01 093900)
- National Cancer Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Keywords
- ovarian carcinoma, mesenchymal stem cells, cancer stem cells, tumor microenvironment, BMP signaling, BMP-2, BMP4, BMP6, carcinogenesis, stem cell recruitment, multipotency
- MeSH terms
- Cell Differentiation, Cell Separation, Female, Humans, Models, Biological, Ovarian Neoplasms, Phenotype, Neoplastic Stem Cells, Signal Transduction, Gene Expression Regulation, Neoplastic, Bone Morphogenetic Proteins, Gene Expression Profiling, Cell Line, Tumor, Tumor Microenvironment, Mesenchymal Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.